Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Colorcon
Baxter
Boehringer Ingelheim
AstraZeneca
McKesson

Last Updated: June 29, 2022

Patent: 10,058,523


✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,058,523
Title:Benzoquinone derivative E3330 in combination with chemotherapeutic agents for the treatment of cancer and angiogenesis
Abstract: Disclosed are novel methods for the therapeutic treatment of cancer and angiogenesis. The enzyme Ape1/Ref-1, via its redox function, enhances the DNA binding activity of transcription factors that are associated with the progression of cancer. The present invention describes the use of agents to selectively inhibit the redox function of Ape1/Ref-1 and thereby reduce tumor cell growth, survival, migration and metastasis. In addition, Ape1/Ref-1 inhibitory activity is shown to augment the therapeutic effects of other therapeutics and protect normal cells against toxicity. Further, Ape1/Ref-1 inhibition is shown to decrease angiogenesis, for use in the treatment of cancer as well other pathologic conditions of which altered angiogenesis is a component.
Inventor(s): Kelley; Mark R. (Zionsville, IN)
Assignee: Indiana University Research and Technology Corporation (Indianapolis, IN)
Application Number:14/690,973
Patent Claims:see list of patent claims

Details for Patent 10,058,523

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. AVASTIN bevacizumab Injection 125085 02/26/2004 See Plans and Pricing 2027-09-26
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Medtronic
Boehringer Ingelheim
Baxter
AstraZeneca
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.